Metal on Metal Versus Ceramic on Metal Hip Replacement

August 6, 2013 updated by: DePuy Orthopaedics

Comparative Study to Evaluate the Safety and Efficacy of the DePuy Ceramic-on-metal Total Hip Prosthesis Versus the DePuy Metal-on-metal Total Hip Prosthesis Through Clinical and Radiographical Data

The purpose of this study is to compare the performance of artificial hips with metal heads and metal sockets to artificial hips with ceramic heads articulating with metal socket components. The success of the total hip arthroplasty (THA) will be based upon all of the following clinical and radiographic criteria being met at the two-year evaluation: (1) the patient's clinical results as measured using modified Harris Hip evaluation rating system, and the absence of a complication that requires the surgical removal or replacement of a component; and (2) radiographic findings at study endpoint (i.e., two years follow-up). Clinical and radiographic success at two (2) years postoperative is required for the study hip to be deemed successful.

Study Overview

Detailed Description

This study is a prospective, multi-center, randomized, single blind, controlled clinical investigation comparing the safety and efficacy of the cementless Ceramic on Metal total hip prostheses versus the cementless Metal on Metal total hip prostheses.

Study Type

Interventional

Enrollment (Actual)

392

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • London, Ontario, Canada, N6A 5A5
    • Arkansas
      • Little Rock, Arkansas, United States, 72203
        • Foundation for Musculoskeletal Research and Education
    • California
      • Orange, California, United States, 92868
    • Florida
      • Palm Bay, Florida, United States, 32905
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
    • Ohio
      • Cincinnati, Ohio, United States, 45236
    • Virginia
      • Alexandria, Virginia, United States, 22306
        • Anderson Clinic
      • Roanoke, Virginia, United States, 24018
    • Washington
      • Spokane, Washington, United States, 99218

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to (or capable of) provide consent to participate in the clinical investigation prior to the day of the surgery.
  • Skeletally mature (tibial and femoral epiphyses are closed)
  • Undergoing cementless primary hip replacement surgery for Noninflammatory Degenerative Joint Disease
  • Affected hip has a Harris Hip Score of 70 or lower and a Pain rating of Moderate or greater
  • Radiographic Parameters:
  • X-Ray Evaluation confirms the presence of NIDJD
  • Femoral and acetabular bone stock is sufficient, regarding strength and shape, and is suitable to receive the implants
  • No structural bone grafts required to support to prosthetic component(s)or to shape the bone to receive implant(s)
  • Willing to have knowledge of treatment arm (CoM or MoM) withheld for a period of 24 months post-operatively unless disclosure is legally and/or medically necessary
  • Previous THA in contralateral hip that is greater than one (1) year postoperative and has a Harris Hip pain rating less than MILD

Exclusion Criteria:

  • Bilateral hip disease with the anticipated need for bilateral hip implant during study participation (i.e., within the next 24 months)
  • THA required for the revision of a previously failed THA
  • Suffering from inflammatory arthritis
  • Prior prosthetic hip replacement
  • Previous Girdlestone procedure or surgical fusion in the operative hip joint
  • Above knee amputation of either the contralateral or ipsilateral leg
  • Known allergy to metal (e.g. jewelry)
  • The presence of highly communicable disease or diseases that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.)
  • Significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis)
  • Conditions that may interfere with the total hip arthroplasty survival or outcome (e.g., Paget's disease, Charcot's disease)
  • Unwilling or unable to comply with a rehabilitation program for a cementless THA or difficulty or inability to return for follow-up visits prescribed by the study protocol
  • Known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser
  • Previous treatment for renal disease
  • Any systemic steroid therapy, excluding inhalers, within three months prior to surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: A
Ceramic-on-metal total hip implant
Total hip replacement
Other Names:
  • Biolox Delta head; Ultamet insert; Pinnacle Acetabular shell
Active Comparator: B
Metal-on-metal total hip implant
Total hip replacement
Other Names:
  • CoCr M-head, Ultamet insert, Pinnacle Acetabular shell

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite Success/Failure
Time Frame: At 24 months
The composite success/failure of the implant was made up of radiographic, clinical and revision data. Radiographic success was determined by femoral subsidence =/< 2mm, acetabular migration =/< 2mm, cup inclination =/< 4°, no acetabular or femoral osteolysis, and acetabular and femoral lucencies less than 50% of visible porous coating. Clinical success was determined by a Harris Hip score equal to or greater than 80. A hip (patient) was considered to be a composite success at study endpoint if it was a radiographic and clinical success and no revision of any component had taken place.
At 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Scott, MD, Orthopaedic Specialty Clinic
  • Principal Investigator: Patrick G Kirk, MD
  • Principal Investigator: Shekhar S Desai, MD
  • Principal Investigator: Charles A Engh, Jr., MD, Anderson Clinic
  • Principal Investigator: Ajai Cadambi, MD, Adult Orthopaedic Reconstruction Texas Hip and Knee Center
  • Principal Investigator: C L Barnes, MD, Foundation for Musculoskeletal Research & Education

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2005

Primary Completion (Actual)

December 1, 2008

Study Completion (Actual)

June 1, 2011

Study Registration Dates

First Submitted

September 13, 2005

First Submitted That Met QC Criteria

September 13, 2005

First Posted (Estimate)

September 21, 2005

Study Record Updates

Last Update Posted (Estimate)

August 14, 2013

Last Update Submitted That Met QC Criteria

August 6, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 03062

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-inflammatory Joint Diseases

Clinical Trials on Total Hip Replacement

3
Subscribe